FARN: Bexmarilimab reports 45% remission in high-risk MDS
FARN said its bexmarilimab achieved 45% remission in high-risk MDS, and that funding has been secured for pivotal trials.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.